

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)



(10) International Publication Number
WO 2022/246433 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 14/47 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2022/072413

(22) International Filing Date:

18 May 2022 (18.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/190,191 18 May 2021 (18.05.2021) US

(71) Applicants: UNIVERSITY OF TENNESSEE

RESEARCH FOUNDATION [US/US]; 400 W Summit Hill Dr., UT Tower 961A, Knoxville, Tennessee 37902 (US). ATTRALUS, INC. [US/US]; 50 Francisco St, Suite 450, San Francisco, California 94133 (US).

(72) Inventors: WALL, Jonathan S.; c/o University of Tennessee Research Foundation, 400 W Summit Hill Dr., UT Tower 961A, Knoxville, Tennessee 37902 (US). FOSTER, James S.; c/o University of Tennessee Research Foundation, 400 W Summit Hill Dr., UT Tower 961A, Knoxville, Tennessee 37902 (US). GUTHRIE, Spencer; c/o Attralus Inc., 50 Francisco St, Suite 450, San Francisco, California 94133 (US). PONS, Jaume; c/o Attralus, Inc., 50 Francisco St, Suite 450, San Francisco, California 94133 (US). KLEIN, Michael L.; c/o Attralus, Inc., 50 Francisco St, Suite 450, San Francisco, California 94133 (US).

(74) Agent: POON, Meghan et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: ANTIBODY-PEPTIDE FUSION PROTEINS FOR TREATING AMYLOID DISORDERS

(57) Abstract: Provided herein are antibody-peptide fusion proteins comprising an amyloid-reactive peptide linked to an antibody. Also provided herein are methods of treating amyloid-based diseases by administering an antibody-peptide fusion protein.




FIG. 3

WO 2022/246433 A1

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*